At AACR 2026, several first-time disclosed oncology programs highlighted how public biotech and pharma companies are positioning for the next wave of innovation. From an investor perspective, the key question remains: Does this asset improve the company’s position in a real, competitive market? Below is a focused look at newly disclosed assets from public companies, through four lenses: disease target, competition, technology, and potential market impact. 🟢 AstraZeneca: Prec

Summary:

Originally posted 2/9/2023; last updated 3/29/23

$XBI $76.23 | +6.18% Table of Contents: Covid Updates Pipeline Updates Business Updates Covid Updates #NVAX +14% Novavax Files...

$XBI $76.23 | +6.18% Table of Contents: Covid Updates Pipeline Updates Business Updates Covid Updates #NVAX +14% Novavax Files...

Summary: FGEN stock was crushed last week on strong votes against Roxadustat in both DD and NDD by FDA AdComm Big-Mover event In battle...